1. Home
  2. MSDL vs ARVN Comparison

MSDL vs ARVN Comparison

Compare MSDL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • ARVN
  • Stock Information
  • Founded
  • MSDL 2019
  • ARVN 2015
  • Country
  • MSDL United States
  • ARVN United States
  • Employees
  • MSDL N/A
  • ARVN N/A
  • Industry
  • MSDL
  • ARVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • ARVN Health Care
  • Exchange
  • MSDL NYSE
  • ARVN Nasdaq
  • Market Cap
  • MSDL 1.9B
  • ARVN 1.8B
  • IPO Year
  • MSDL N/A
  • ARVN 2018
  • Fundamental
  • Price
  • MSDL $20.83
  • ARVN $18.48
  • Analyst Decision
  • MSDL Buy
  • ARVN Strong Buy
  • Analyst Count
  • MSDL 7
  • ARVN 13
  • Target Price
  • MSDL $21.67
  • ARVN $63.00
  • AVG Volume (30 Days)
  • MSDL 418.3K
  • ARVN 967.8K
  • Earning Date
  • MSDL 01-01-0001
  • ARVN 10-30-2024
  • Dividend Yield
  • MSDL 9.60%
  • ARVN N/A
  • EPS Growth
  • MSDL N/A
  • ARVN N/A
  • EPS
  • MSDL N/A
  • ARVN N/A
  • Revenue
  • MSDL N/A
  • ARVN $161,100,000.00
  • Revenue This Year
  • MSDL $1,597.39
  • ARVN $237.44
  • Revenue Next Year
  • MSDL $8.41
  • ARVN N/A
  • P/E Ratio
  • MSDL N/A
  • ARVN N/A
  • Revenue Growth
  • MSDL N/A
  • ARVN 1.07
  • 52 Week Low
  • MSDL $19.05
  • ARVN $17.37
  • 52 Week High
  • MSDL $24.18
  • ARVN $53.08
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 49.59
  • ARVN 32.78
  • Support Level
  • MSDL $21.03
  • ARVN $17.37
  • Resistance Level
  • MSDL $21.62
  • ARVN $19.21
  • Average True Range (ATR)
  • MSDL 0.40
  • ARVN 1.64
  • MACD
  • MSDL -0.08
  • ARVN -0.59
  • Stochastic Oscillator
  • MSDL 21.78
  • ARVN 11.80

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Share on Social Networks: